

## NASPE POSITION PAPER

---

# Clinical Cardiac Electrophysiology Fellowship Teaching Objectives for the New Millennium

MARK S. LINK, M.D., CHARLES ANTZELEVITCH, Ph.D., ALBERT L. WALDO, M.D., AUGUSTUS O. GRANT, M.D., JOHN P. DiMARCO, M.D., MARK E. JOSEPHSON, M.D., FRANCIS E. MARCHLINSKI, M.D., HASAN GARAN, M.D., PHILIP T. SAGER, M.D., DWIGHT W. REYNOLDS, M.D., PABLO DENES, M.D., MELVIN M. SCHEINMAN, M.D., and N.A. MARK ESTES III, M.D.

### Introduction

The field of cardiac electrophysiology has grown and changed dramatically since the last guideline on fellowship training objectives was published in 1988. Not only has the ability to diagnose arrhythmic diseases improved, but also the knowledge of genetic contributions and mechanisms of these disorders has expanded. Moreover, the treatment of these arrhythmias, including ablation and implantable cardioverter defibrillators (ICDs), has forever altered patient management. The purpose of this updated fellowship teaching objective is to outline the basic science, clinical components, and procedural aspects of electrophysiology and to provide relevant references that can be used as an educational guide. This work represents a compilation by experts in the field of electrophysiology but is not intended to give guidelines regarding fellowship requirements outlined in American Board of Internal Medicine (ABIM) and ACGME documents.

This article is organized according to the following sections: (1) historical aspects of electrophysiology; (2) disease mechanisms, including basic electrophysiology and the genetic basis of arrhythmias; (3) diagnosis of arrhythmias, including surface ECG, invasive electrophysiologic evaluation, and laboratory safety; (4) treatment of arrhythmias, including basic pharmacokinetics and pharmacodynamics, ablation of supraventricular tachycardia, atrial fibrillation and flutter, ablation of ventricular tachycardia (VT), pacemakers, and ICDs; and (5) syncope and sudden cardiac death.

### Historical Aspects

Fellows should be familiar with the early works of the investigators who laid the foundation and ideas for clinical electrophysiology and whose ideas were the cradle for the future generations of cardiac electrophysiologists.<sup>1-3</sup>

A. External and internal pacemaker introduction in the 1960s by Zoll, Bakken, and Furman.

- B. Scherlag and co-workers in 1969 reported on the catheter technique to record His-bundle activity in man.
- C. Wellens published the classic text on the use of programmed electrical stimulation of the heart by intracardiac catheters in the diagnosis and treatment of tachycardias.
- D. Gallagher and Sealy developed and widely applied the endocardial surgical approach to the treatment of patients with the Wolff-Parkinson-White (WPW) syndrome.
- E. Josephson and Harken studying patients with ischemic heart disease and VT developed the technique of endocardial excision, guided by preoperative and intraoperative mapping.
- F. Guiraudon and Klein developed an epicardial approach to the surgical treatment of patients with WPW syndrome.
- G. In 1980, Mirowski and co-workers reported on the implantation of an automatic defibrillator for the management of malignant ventricular arrhythmias in humans.
- H. Intracardiac ablation developed in early 1980s by Scheinman and Gallagher.

### References

1. Jeffrey K: Cardiac pacing and electrophysiology at millennium's end: Historical notes and observations. *PACE* 1999;22:1713-1717.
2. Luderitz B: *History of the Disorders of Cardiac Conduction*. Futura Publishing Co., Armonk, NY, 1995.
3. Zipes DP, Wellens HJ: What have we learned about cardiac arrhythmias? *Circulation* 2000;102:IV-52-IV-57.

### Disease Mechanisms

#### I. Basic Electrophysiology

Fellows should possess an understanding of the basic cellular and molecular mechanisms of electrophysiology. These concepts include the cellular and molecular bases for electrical function of the heart under normal and pathophysiological conditions, the mechanisms responsible for the development of arrhythmias, and the actions of antiarrhythmic drugs.

- A. Determinants of the normal action potential and normal cardiac rhythm
  1. Genesis of the resting potential in excitable cells<sup>1</sup>
  2. Channels and ionic currents responsible for the action potential<sup>2</sup>

- 3. Genes encoding for cardiac ion channels, exchangers, and pumps<sup>3</sup>
- 4. Electrical heterogeneity<sup>4</sup>
- 5. Mechanisms of automaticity in nodal and Purkinje pacemakers
- B. Determinants of normal conduction
  - 1. Structure and function of gap junctions
  - 2. Passive membrane properties and electrotonic interactions
  - 3. Anisotropy<sup>5</sup>
  - 4. Modulation of these factors by sympathetic and parasympathetic agonists
- C. Cellular basis for the inscription of the ECG<sup>4</sup>
  - 1. QRS
  - 2. T wave and ST segment
  - 3. J wave
  - 4. U wave
- D. Genesis of cardiac arrhythmias<sup>6,7</sup>
  - 1. Mechanisms of cardiac arrhythmia
    - a. Abnormalities of impulse formation
      - i. Abnormal automaticity
        - a) Enhanced pacemaker activity
        - b) Protected pacemaker activity (parasystole)
      - ii. Triggered activity
        - a) Early afterdepolarizations
        - b) Delayed afterdepolarizations
    - b. Reentrant arrhythmias
      - i. Circus movement arrhythmia
      - c) Anatomic obstacle (ring model)
      - d) Functional block (leading circle, figure of eight, spiral/rotor)
      - ii. Reflection
      - iii. Phase 2 reentry
  - 2. Congenital and acquired arrhythmia syndromes
    - c. Gene mutations in ion channels, exchangers, pumps
      - i. Long QT syndrome (LQTS)<sup>8</sup>
      - ii. Brugada syndrome<sup>9</sup>
      - iii. Conduction system disease
    - d. Drug-induced arrhythmia syndromes
    - e. Autonomic nervous system-mediated arrhythmias
    - f. Ischemia- and infarction-related arrhythmias
  - E. Antiarrhythmic drug actions
    - 1. Mechanisms of action of antiarrhythmic drugs
      - a. Drug-receptor interactions
      - b. Effects on conduction, repolarization, automaticity, and contractility<sup>10</sup>
    - 2. Gene-specific pharmacologic therapy<sup>3</sup>
    - 3. Modulation of drug effects by metabolic alterations (e.g., pH, and K<sup>+</sup>), rate, or changes in resting potential
- 4. Antzelevitch C, Dumaine R: Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. In Page E, Fozard HA, Solaro RJ, eds: *Handbook of Physiology. The Heart*. Oxford University Press, New York, 2000.
- 5. Spach MS: Anisotropy of cardiac tissue: A major determinant of conduction? *J Cardiovasc Electrophysiol* 1999;10:887-890.
- 6. Antzelevitch C, Burashnikov A: Mechanisms of arrhythmogenesis. In Podrid PJ, Kowey PR, eds: *Cardiac Arrhythmia: Mechanism, Diagnosis and Management*. William & Wilkins, Baltimore, 2000.
- 7. Jalife J: Ventricular fibrillation: Mechanisms of initiation and maintenance. *Annu Rev Physiol* 2000;62:25-50.
- 8. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation* 2000;102:1178-1185.
- 9. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin JA: *The Brugada Syndrome*. Futura Publishing Co., Armonk, NY, 1999, pp. 1-99.
- 10. Nattel S: The molecular and ionic specificity of antiarrhythmic drug actions. *J Cardiovasc Electrophysiol* 1999;10:272-282.

## II. Genetic Basis of Arrhythmias

Identification of the molecular basis of inherited arrhythmias represents one of the most significant advances in cardiovascular research in the past 25 years and illustrates the symbiotic relationship between basic and clinical sciences.<sup>1-3</sup> Unraveling the molecular basis of several inherited arrhythmias was instrumental in characterizing certain ionic currents that control cardiac repolarization. To date, most of the focus in genetic research of cardiac arrhythmias is on the monogenetic disorders in which single mutations result in arrhythmias. The much more common issue may be the role of gene polymorphisms in arrhythmia susceptibility and adverse response to drugs.

- A. The fellow should be familiar with the following background materials:
  - 1. Original descriptions of the LQTS<sup>4-6</sup> and Brugada syndromes<sup>7</sup>
  - 2. Role of specific ion channels in the generation of the normal action potential
  - 3. Regional differences in the cardiac action potential
  - 4. Relationship between the action potential and the surface ECG
- B. Role of specific ion channel mutations in the genesis of arrhythmias
  - 1. Inherited defects in potassium channel and their subunits as a basis for LQTS<sup>6</sup>
  - 2. Inherited defects in sodium channels as a basis for LQT3 and Brugada syndrome<sup>1-3</sup>
- C. Additional areas of investigation that are under active research.
  - 1. Lev-Lenegre disease
  - 2. Atrial fibrillation<sup>8</sup>
  - 3. WPW syndrome<sup>9</sup>

## References

1. Sperelakis N: Basis of the cardiac resting potential. In Sperelakis N, ed: *Physiology and Pathophysiology of the Heart*. Kluwer Academic Publishers, Norwell, MA, 1995, pp. 55-76.
2. Luo CH, Rudy Y: A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. *Circ Res* 1994;74:1071-1096.
3. Priori SG, Barhanin J, Hauer RNW, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AAM: Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II. *Circulation* 1999;99:518-528.

1. Priori SG, Barhanin J, Hauer R, Haverkamp W, Jongsma HJ, Habo J, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM: Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II. *Circulation* 1999;99:518-528.
2. Priori SG, Barhanin J, Hauer R, Haverkamp W, Jongsma HJ, Habo J, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM: Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management part III. *Circulation* 1999;99:674-681.

## References

3. Kirsch GE: Ion channel defects in cardiac arrhythmias. *J Membr Biol* 1999;170:181-190.
4. Jervel A, Lange-Nielsen F: Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. *Am Heart J* 1957;54:59-68.
5. Ward OC: A new familial cardiac syndrome in children. *J Irish Med Assoc* 1964;54:103-106.
6. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrums of mutations in long-QT syndrome genes *KVLQT1*, *HERG*, *SCN5A*, and *KCNE2*. *Circulation* 2000;102:1178-1185.
7. Brugada J, Brugada R, Brugada P: Right bundle-branch block and ST-segment elevation in leads V<sub>1</sub> through V<sub>3</sub>. *Circulation* 1998;97:457-460.
8. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, Brugada J, Girona J, Domingo A, Bachinski LL, Roberts R: Identification of a genetic locus for familial atrial fibrillation. *N Engl J Med* 1997;336:905-911.
9. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozano R, Shah G, Fananapazir L, Bachinski LL, Roberts R, Hassan AS: Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. *N Engl J Med* 2001;344:1823-1831.

## Diagnosis of Arrhythmias

### I. Surface ECG of Arrhythmias

Fellows should meet minimum competency requirements of a general cardiology fellow for ECG interpretation as outlined by the American College of Cardiology Task Force.<sup>1</sup> Fellows are expected to be fully familiar with the indications and performance of a variety of noninvasive ECG tests.

- A. Surface ECG interpretation
  1. Evaluation of normal and abnormal intervals
  2. Recognition of myocardial infarction and evidence of ischemia
  3. Metabolic/drug effects
  4. Conduction disturbances
  5. Identification of accessory AV connection location
- B. Noninvasive ECG tests
  1. Ambulatory ECG recordings
  2. Continuous on-line ECG monitoring (telemetry)
  3. Manually and automatically activated event recorders
  4. Analysis of signal-averaged ECGs
  5. Exercise testing for the presence of myocardial ischemia and/or arrhythmias
  6. Heart rate variability as a risk stratifier
  7. T wave alternans as a risk stratifier
- C. Bradyarrhythmias
  1. Abnormalities of sinus node function, including inappropriate sinus bradycardia, sinus arrest, and sinus exit block
  2. Abnormalities of AV conduction and their localization to the AV node, His bundle, or His-Purkinje system
- D. Tachyarrhythmias
  1. Recognition of atrial tachycardia, reentrant arrhythmias using manifest or concealed AV connection pathways, and AV nodal reentrant tachycardias (AVNRT)
  2. Typical and reverse typical (isthmus dependent) atrial flutter, lesion reentry, left atrial, and atypical flutters<sup>2</sup>
  3. Atrial fibrillation with particular reference to focal origins

4. Wide QRS complex tachycardia with specific attention paid to distinguishing VT from supraventricular tachycardia with aberrant ventricular conduction and ventricular preexcited tachycardias. Specific ventricular arrhythmias include:
  - a. Ventricular ectopy with specific attention to bigeminy and parasystole.
  - b. Nonsustained VT (monomorphic or polymorphic) with or without associated long QT intervals
  - c. Sustained VT with particular attention to idiopathic VT versus tachycardia associated with organic heart disease
  - d. Sustained polymorphic VT with or without long QT intervals
  - e. Bidirectional VT and other drug-induced tachycardias

### E. Miscellaneous arrhythmogenic situations

1. LQTS; specific patterns of T waves related to gene defect
2. Brugada syndrome
3. Arrhythmogenic right ventricular dysplasia
4. Idiopathic ventricular fibrillation

## References

1. Fisch C, Ryan TJ, Williams SV, Achord JL, Akhtar M, Crawford MH, Friesinger GC, Holzinger EJ, Klocke FI, Kowey PR, Lavizzo-Mourey RJ, Leonard J, O'Connell JB, O'Rourke RA, Reynolds WA, Scanlon PJ, Schlant RC, Ware DE: Clinical competency in electrocardiography. *Circulation* 1995;91:2683-2686.
2. Saoudi N, Cosio F, Waldo A, Chen SA, Isaka Y, Lesh M, Saksena S, Salerno J: Classification of atrial flutter and regular atrial tachycardia according to electrophysiologic and anatomical basis. A statement from a joint expert group from the working group of arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur Heart J* 2001;22:1162-1182 and *J Cardiovasc Electrophysiol* 2001;12:852-866.

### II. Invasive Electrophysiologic Evaluation

Electrophysiology fellows should be able to list the indications for invasive electrophysiologic studies; perform a comprehensive electrophysiologic study; interpret the data derived from such studies; indicate the sensitivity and specificity of these findings; and integrate these findings into the clinical care of the patient.

- A. Principles of recording
  1. Genesis of the intracardiac recording
  2. Types of recordings
    - a. Unipolar
    - b. Bipolar
      - i. Effect of electrode spacing
      - ii. Effect of electrode orientation (linear, orthogonal)
  3. Filtering
    - a. Bandpass and its effect on signal content
    - b. Notch filter
  4. Gain and clipping of recorded signal
  5. Electrode field and concept of local activation time
- B. Principles of stimulation
  1. Concept of threshold
  2. Types of stimulation and implications for pace mapping
    - a. Unipolar
    - b. Bipolar
- C. Sinus node function

1. Obtaining and evaluating the sinus node recovery time, sinus atrial conduction time, and sinus node electrogram<sup>1,2</sup>
- D. AV node and AV nodal-dependent tachycardias
  1. Intra-atrial versus AV nodal conduction disease<sup>3</sup>
  2. AV nodal function and dysfunction in response to atrial overdrive pacing<sup>4</sup>
  3. AVNRT
  4. AV reentrant tachycardia
- E. His-Purkinje system
  1. Diagnose conduction delay or block as within the AV node or His-Purkinje system, and integrate this information with regard to need for permanent cardiac pacing<sup>5</sup>
- F. Ventricular arrhythmias
  1. Detail the number of sites and standard stimulation protocol for induction of VT
  2. Recognize the value of His-bundle and atrial recordings in the diagnosis of VT and/or bundle branch reentry
  3. Detail the sensitivity and specificity of induction protocols with respect to clinical presentation (VT, sustained and nonsustained, or ventricular fibrillation) and underlying myocardial substrate<sup>6</sup>
- G. Principles of resetting of tachycardias
  1. Single-beat resetting methods
  2. Resetting curves and their interpretation
    - a. Flat
    - b. Increasing
    - c. Mixed flat and increasing
    - d. Decreasing
  3. Use of resetting in mapping
- H. Principles of entrainment of tachycardias<sup>7,8</sup>
  1. Definition of entrainment<sup>8-10</sup>
    - a. Constant fusion during pacing at a constant rate faster than the tachycardia except for the last captured beat that is not fused
    - b. Progressive fusion
    - c. Interruption of tachycardia by overdrive pacing associated with localized conduction block to a site followed by activation of that site by the next pacing impulse from a different direction and with a shorter conduction time
    - d. Change in conduction time and electrogram morphology at one recording site when pacing from another site at two different constant pacing rates, each of which is faster than the spontaneous rate of the tachycardia, but fails to interrupt it (electrogram equivalent of progressive fusion)
  2. Techniques of entrainment
    - a. Pacing technique and assurance of capture
    - b. Types of ECG/intracardiac fusion and their implications
      - i. Fixed fusion
      - ii. Progressive fusion
      - iii. Concealed entrainment
  3. Implications of entrainment
    - a. Presence of reentry
    - b. Significance for mapping

## References

1. Mandel W, Hayakawa H, Allen HN, Danzig R, Marcus HS: Evaluation of sinoatrial node function in man overdrive suppression. *Circulation* 1971;44:59-65.
2. Strauss HC, Bigger JT, Saroff AL, Giardina EGV: Electrophysiology evaluation of sinus node function in patients with sinus node dysfunction. *Circulation* 1976;53:763-776.
3. Narula OS, Runge M, Samet P: Second degree Wenckebach-type AV block due to block within the atrium. *Br Heart J* 1972;34:1127-1136.
4. Reddy CP, Damato AN, Akhtar M, Ogunkelu JB, Caracta AR, Ruskin JN, Lau SH: Time dependent changes in the functional properties of the atrioventricular conduction system in man. *Circulation* 1975;52: 1012-1022.
5. Scheinman MM, Peters RW, Sauve MJ, Desai J, Abbott JA, Cogan J, Wohl B, William K: Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. *Am J Cardiol* 1982;50:1316-1322.
6. Waldo AL, Akhtar M, Brugada P, Henthorn RW, Scheinman MM, Ward DE, Wellens HJJ: The minimally appropriate electrophysiologic study for the initial assessment of patients with documented sustained monomorphic ventricular tachycardias. *J Am Coll Cardiol* 1985;6: 1174-1177.
7. Stevenson WG, Friedman PL, Sager PT, Saxon LA, Kocovic D, Harada T, Wiener I, Khan H: Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. *J Am Coll Cardiol* 1997;29:1180-1189.
8. Waldo AL, Plumb VJ, Arceñas JG, MacLean WAH, Cooper TB, Priest MF, James TN: Transient entrainment and interruption of the atrioventricular bypass tract type of paroxysmal atrial tachycardia: A model for understanding and identifying reentrant arrhythmias in man. *Circulation* 1983;67:73-83.
9. Henthorn RW, Okumura K, Olshansky B, Waldo AL: A fourth criterion for transient entrainment: The electrogram equivalent of progressive fusion. *Circulation* 1988;77:1003-1012.
10. Waldo AL, Henthorn RW, Plumb VJ, MacLean WAH: Demonstration of the mechanism of transient entrainment and interruption of ventricular tachycardias with rapid atrial pacing. *J Am Coll Cardiol* 1984;3: 422-430.

## III. Laboratory Safety

In the laboratory, procedures utilize radiation and include the potential for transmission of disease. Therefore, electrophysiology fellows should be aware of laboratory safety as related to radiation exposure to patients, self, and other staff, and the risks and prevention of transmissible disease.

- A. Radiation exposure<sup>1-3</sup>
  1. Principles of radiation safety
  2. Reduction of exposure to medical personnel
  3. Precautions for medical employees during pregnancy
  4. Radiation risks for patients
    - a. Cancer
    - b. Genetic defects
    - c. Radiation-induced skin injury
- B. Precautions for transmissible diseases
  1. Hepatitis, human immunodeficiency virus, spongiform encephalopathy
  2. Shielding from bodily fluids
  3. Needle precautions
  4. Disposal of contaminated supplies
  5. Treatment and follow-up of medical personnel after exposure to bodily fluids

## References

1. Cardella JF, Miller DL, Cole PE, Lewis CA: Society of Cardiovascular and Interventional Radiology position statement on radiation safety. *J Vasc Interv Radiol* 2001;12:281.
2. Bates ER, Berger PB, Clark DA, Cusma JT, Dehmer GJ, Kern MJ, Laskey WK, O'Laughlin MP, Oesterle S, Popma JJ: American College of Cardiology/Society for Cardiac Angiography and Interventions

- clinical expert consensus document on cardiac catheterization laboratory standards. *J Am Coll Cardiol* 2001;37:2170-2214.
3. Limacher MC, Douglas PS, Germano G, Laskey WK, Lindsay BD, McKetty MH, Moore ME, Park JK, Prigent FM, Walsh MN: Radiation safety in the practice of cardiology: ACC expert consensus document. *J Am Coll Cardiol* 1998;31:892-913.

## Treatment of Arrhythmias

### I. Basic Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and pharmacodynamics are essential concepts in understanding therapeutic drug delivery. Although drugs are less commonly used clinically as a first-line basis for ventricular arrhythmias, they frequently are utilized as adjunctive therapy for ventricular arrhythmias. In addition, antiarrhythmic agents will likely continue to be frequently utilized for atrial fibrillation.

#### A. Basic pharmacokinetic principles<sup>1,2</sup>

1. Absorption of drugs from the gastrointestinal tract and from intramuscular sites
  - a. Effects of lipid solubility/ionic charge
  - b. Effects of drugs that alter gastrointestinal blood on drug absorption
2. Distribution of drugs after administration
  - a. Concepts of apparent volumes of distribution and absence of their relationships to anatomic volumes
  - b. Effects of tissue and plasma protein binding
3. Metabolism of drugs by hepatic and extrahepatic mechanisms
  - a. First-pass hepatic metabolism and its effects of oral medications
  - b. Role of the cytochrome P450 system and other metabolic pathways in drug metabolism
  - c. Pharmacogenetic patterns that may influence drug metabolism
  - d. Induction and inhibition of drug metabolism by diet, alcohol, and other drugs
4. Elimination of drugs by liver, kidney, and lungs
  - a. Relationship between elimination rate constant and  $t_{1/2}$
  - b. Clinical relevance of dose-dependent (or concentration-dependent) kinetics (saturable processes)
  - c. Role of P glycoprotein and other drug transport systems

#### B. Clinical pharmacokinetics<sup>3-6</sup>

1. Dosing recommendations and therapeutic decisions based on the following concepts:
  - a. Clearance as a determinant of steady-state plasma concentration (renal, nonrenal, and systemic)
  - b. Half-life time relationship to time to steady state
  - c. Basic concepts of compartmental analysis
  - d. Use and abuse of loading doses
  - e. Principles of therapeutic drug level monitoring
  - f. Drug interactions
2. Information necessary to consider the effect of the following factors on pharmacokinetics in selecting drugs and drug dosages
  - a. Age
  - b. Gender
  - c. Renal function
  - d. Hepatic function
  - e. Cardiac disease

- C. Pharmacodynamics: Basic concepts of drug actions
  1. Receptor theory
  2. Log dose-response relationships
  3. Agonists
  4. Antagonists (competitive and noncompetitive)
  5. Interactions of drugs with ionic channels
- D. Pharmacodynamics and pharmacokinetics of antiarrhythmic drugs
  1. Utility and limitations of various classification schemes: Vaughan-Williams, Sicilian Gambit, etc.<sup>7</sup>
  2. Effects of drugs on cardiac ion channels
  3. Differential effects of drugs on conduction and refractoriness of atrial and ventricular myocardium, bypass tracts, and His-Purkinje tissue
  4. Effects of drugs in situations with potentially abnormal electrophysiology, e.g., abnormal repolarization syndromes, ischemia, hypertrophy
  5. Effects of drugs on atrial and ventricular defibrillation thresholds
  6. The following information for individual antiarrhythmic agents in normal subjects and in patients with renal, hepatic, or heart failure:
    - a. Indications
    - b. Contraindications
    - c. Dosages
    - d. Drug interactions
    - e. Diagnosis and management of potential adverse effects
    - f. Pathways for metabolism and elimination
    - g. Range of expected elimination  $t_{1/2}$
- E. Drug-device interactions
  1. The trainee should be familiar with the effects of cardiovascular drugs on both sensing and therapeutic functions of pacemakers and ICDs.<sup>8</sup>

## References

1. Nakagawa K, Ishizaki T: Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. *Pharmacol Ther* 2000;86:1-28.
2. Nolan PE Jr: Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. *Pharmacotherapy* 1997;17(2 Pt 2):65S-75S, discussion 89S-91S.
3. Kowey PR, Marinchak RA, Rials SJ, Bharucha DB: Classification and pharmacology of antiarrhythmic drugs. *Am Heart J* 2000;140:12-20.
4. Van Gelder IC, Brugemann J, Crijns HJ: Current treatment recommendations in antiarrhythmic therapy. *Drugs* 1998;55:331-346.
5. Singh BN: Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. *J Cardiovasc Electrophysiol* 1999;10:283-301.
6. Abernathy DR, Flockhart DA: Molecular basis of cardiovascular drug metabolism: Implications for predicting clinically important drug interactions. *Circulation* 2000;101:1749-1753.
7. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. *Circulation* 1991;84:1831-1851.
8. Movsowitz C, Marchlinski FE: Interactions between implantable cardioverter-defibrillators and class III agents. *Am J Cardiol* 1998;82(4A):41I-48I.

### II. Ablation of Supraventricular Tachycardia

A knowledge of which patients should undergo radiofrequency ablation and of the techniques and endpoints for ablation should be well known to clinical electrophysiology fellows.<sup>1</sup> In addition, the techniques of ablation, including mapping, knowledge of newer mapping technologies, ret-

rograde access to the left atrium and ventricle, and transseptal puncture should be familiar to the fellows.

- A. Patient selection and preablation work-up, including cardiac monitoring, exercise stress testing, echocardiography, and even cardiac catheterization in selected individuals
- B. Equipment
  - 1. Catheters types and associated curves
  - 2. Sheaths, including curves and uses
  - 3. Energy sources
- C. Anatomy<sup>2</sup>
  - 1. Epicardial coronary vessels
  - 2. Atrial anatomy
    - a. AV node and His bundle
    - b. Triangle of Koch
    - c. Isthmus
    - d. Crista terminalis
    - e. Pulmonary veins
    - f. Coronary sinus
    - g. Sinus node
- D. Techniques and endpoints
  - 1. AVNRT<sup>3,4</sup>
    - a. Types
      - i. Slow/fast
      - ii. Fast/slow
      - iii. Slow/slow
      - iv. Other variants
    - b. Ablation of AVNRT
      - i. Slow pathway (preferred method)
      - ii. Fast pathway
    - c. Mapping techniques for radiofrequency ablation
      - i. Slow potential guided
      - ii. Anatomically guided
    - d. Relative accuracy of endpoints of ablation
      - i. Noninducibility
      - ii. Junctional AV beats during ablation
      - iii. Elimination of slow pathway
  - 2. AV reentrant tachycardia<sup>5-7</sup>
    - a. Types
      - i. Orthodromic
      - ii. Antidromic
      - iii. Mahaim fibers
    - b. Mapping techniques
      - i. Anterograde activation mapping of the earliest ventricular activity
      - ii. Retrograde activation mapping of the earliest atrial activity
    - c. Left-sided approaches
      - i. Transseptal
      - ii. Transaortic valve retrograde
  - 3. Atrial tachycardia<sup>8</sup>
    - a. Locations are frequently pulmonary vein insertions and crista terminalis
    - b. Mapping
    - c. Endpoints
  - 4. Atrial flutter and atrial fibrillation (see appropriate sections)
  - E. Maneuvers to distinguish supraventricular tachycardia mechanism<sup>9</sup>
    - 1. Classification schemes
      - a. Long RP versus short RP
      - b. Wide QRS complex versus narrow QRS complex

- 2. Maneuvers
  - a. His refractory ventricular pacing (for wide complex tachycardia) and atrial pacing (for narrow QRS complex)
  - b. Changes in tachycardia cycle length and VA time with bundle branch block
  - c. Para-Hisian pacing
- F. Complications related to supraventricular tachycardia ablation
  - 1. Risk of heart block
  - 2. Risk of stroke
  - 3. Pericardial tamponade

## References

1. Morady F: Radio-frequency ablation as treatment for cardiac arrhythmias. *N Engl J Med* 1999;340:534-544.
2. Cosio FG, Anderson RH, Kuck KH, Becker A, Benditt DG, Bharati S, Borggrefe M, Campbell RW, Gaita F, Guiraudon GM, Haissaguerre M, Klein G, Langberg J, Marchlinski R, Rufilanchas JJ, Saksena S, Thiene G, Wellens HJ: ESCWGA/NASPE experts consensus statement: Living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. *J Cardiovasc Electrophysiol* 1999;10: 1162-1170.
3. Akhtar M, Jazayeri MR, Sra J, Blank Z, Deshpande S, Dhala A: Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. *Circulation* 1993;88:282-295.
4. Jackman WM, Beckman KJ, McClelland JH, Wang X, Friday KJ, Roman CA, Moulton KP, Twidale N, Hazlitt A, Prior MI, Oren J, Overholt ED, Lazzara R: Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radio-frequency catheter ablation of slow-pathway conduction. *N Engl J Med* 1992;327:313-318.
5. Jackman WM, Xunzhang W, Friday KJ, Roman CA, Carlos A, Moulton KP, Beckman KJ, McClelland JH, Twidale N, Hazlitt A, Prior MI, Margolis PD, Calame JD, Overholt ED, Lazzara R: Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White Syndrome) by radiofrequency current. *N Engl J Med* 1991;324:1605-1611.
6. Calkins H, Sousa J, El-Atassi R, Rosenheck S, deBuiteler M, Kou WH, Kadish AH, Langberg JJ, Morady F: Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardia during a single electrophysiology test. *N Engl J Med* 1991;324:1612-1618.
7. Waldo AL, Akhtar M, Benditt DG, Brugada P, Camm AJ, Gallagher JJ, Gillette PC, Klein GJ, Levy S, Scheinman MM, Wellens HJJ, Zipes DP: Appropriate electrophysiologic study and treatment of patients with the Wolff-Parkinson-White Syndrome. *J Am Coll Cardiol* 1988; 11:1124-1129 and *PACE* 1988;11:536-543.
8. Lesh MD, Van Hare GF, Epstein LM, Fitzpatrick AP, Scheinman MM, Lee RJ, Kwasman MA, Grogin HR, Griffin JC: Radiofrequency catheter ablation of atrial arrhythmias: Results and mechanisms. *Circulation* 1994;89:1074-1089.
9. Knight BP, Ebinger M, Oral H, Kim MH, Sticherling C, Pelosi F, Michaud GF, Strickberger SA, Morady F: Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia. *J Am Coll Cardiol* 2000;36:574-582.

## III. Atrial Fibrillation and Flutter

Fellows should possess a sound understanding of atrial fibrillation and flutter. The understanding and therapy of atrial fibrillation is an area of intense research and fellows are expected to be aware of developments as they relate to clinical practice. Technical skills in atrial fibrillation ablation would be an ideal goal.

- A. Atrial fibrillation
  - 1. Mechanisms<sup>1,2</sup>
    - a. Multiple reentrant wavelets
    - b. Fibrillatory conduction from a single rapid focus or reentrant circuit of very short cycle length
    - c. Atrial remodeling
  - 2. Epidemiology

- a. Age-associated prevalence
- b. Associated clinical states (hypertension, valvular disease, congestive heart failure, coronary artery disease, post open heart surgery, etc.)
- 3. Associated potential risks
  - a. Systemic embolism and stroke
  - b. Tachycardia-mediated cardiomyopathy
  - c. Increased mortality
- 4. Diagnosis
- 5. Therapy<sup>3,4</sup>
  - a. Anticoagulation
    - i. Five primary prevention trials and their meta-analysis<sup>5,6</sup>
    - ii. Warfarin to achieve international normalized ratio (INR) of 2 to 3; risks and benefits
    - iii. Questionable value of aspirin
  - b. Antiarrhythmic drugs (suppression)<sup>7</sup>
  - c. Ventricular rate control
    - i. Beta-adrenergic blocking agents, calcium channel blockers, digoxin
    - ii. AV node/His-bundle ablation
  - d. Devices
    - i. Atrial pacing
    - ii. Atrial defibrillation<sup>8</sup>
  - e. Ablation
    - i. Surgical maze
    - ii. Endocardial catheter techniques
      - a) Maze equivalent and its variants (linear ablations)
      - b) Focal ablation (pulmonary vein, superior vena cava, crista terminalis, etc.)<sup>9,10</sup>
      - c) Pulmonary vein isolation<sup>11,12</sup>
  - f. Cardioversion
    - i. Transthoracic
    - ii. Intrathoracic
    - iii. Pre and post anticoagulation

## References

1. Waldo AL: Experimental models of atrial fibrillation: What have we learned? *Semin Interv Cardiol* 1997;2:195-201.
2. Wiffjels M, Kirchhof C, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995;92:1954-1968.
3. Prystowsky EN, Benson W Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse G: Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association. *Circulation* 1996;93:1262-1273.
4. Waldo AL: Modern management of atrial fibrillation. In Braunwald E, series ed. *Heart Disease*. Fifth Edition, Update. WB Saunders, Philadelphia, 1999, pp. 1-12.
5. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson KA, Bass EB: Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. *J Gen Intern Med* 2000;15:56-67.
6. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. *Ann Intern Med* 1999;131:492-501.
7. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. *J Am Coll Cardiol* 1992;20:527-532.
8. Wellens HJJ, Lau C-P, Luderitz B, Akhtar M, Waldo AL, Camm AJ, Timmermans C, Tse H-F, Jung W, Jordaeins L, Ayers G: Atrioverter. An implantable device for the treatment of atrial fibrillation. *Circulation* 1998;98:1651-1656.
9. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;339:659-666.

10. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T, Hocini M, Peng JT, Roudaut R, Clementy J: Electrophysiologic end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary foci. *Circulation* 2000;101:1409-1417.
  11. Pappone C, Rosanio S, Oreti G, Tocchi M, Gugliotta F, Vicidomini G, Salvati A, Dicandia C, Mazzone P, Santinelli V, Gulletta S, Chierchia S: Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. *Circulation* 2000;102:2619-2628.
  12. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I, Chauvin M, Garrigue S, Clementy J: Electrophysiologic breakthroughs from the left atrium to the pulmonary veins. *Circulation* 2000;102:2463-2465.
- B. Atrial flutter
1. Nomenclature and mechanisms<sup>1-4</sup>
    - a. Typical
    - b. Reverse typical
    - c. Lesion
    - d. Left atrial
    - e. Atypical (upper loop, etc.)
  2. Epidemiology
  3. Associated potential risks
    - a. Systemic embolism and stroke<sup>5</sup>
    - b. Tachycardia-mediated cardiomyopathy
    - c. Development of atrial fibrillation
  4. Diagnosis
  5. Therapy
    - a. Anticoagulation
      - i. Five primary prevention trials and their meta-analysis
      - ii. Warfarin: INR 2 to 3; risks and benefits
      - iii. Questionable value of aspirin
    - b. Antiarrhythmic drugs (suppression)
    - c. Ventricular rate control
      - i. Drugs
      - ii. AV node/His-bundle ablation
    - d. Devices
    - e. Ablation<sup>6-8</sup>
      - i. Mapping techniques to identify nature of atrial flutter, its anatomically vulnerable site, and demonstration of postablation efficacy
      - ii. Importance of subeustachian isthmus block for isthmus-dependent flutter
    - f. Cardioversion
    - g. Antitachycardia pacing

## References

1. Kalman JM, Ogin JE, Saxon LA, Fisher WG, Lee RJ, Lesh MD: Activation and entrainment mapping defines the tricuspid annulus as the anterior boundary in atrial flutter. *Circulation* 1996;94:398-406.
2. Waldo AL: Pathogenesis of atrial flutter. *J Cardiovasc Electrophysiol* 1998;9:518-525.
3. Chan DP, Van Hare GF, Mackall JA, Carlson MD, Waldo AL: Importance of atrial flutter isthmus in post-operative intra-atrial reentrant tachycardia. *Circulation* 2000;102:1283-1289.
4. Waldo AL, MacLean WAH, Karp RB, Kouchoukos NT, James TN: Entrainment and interruption of atrial flutter with atrial pacing: Studies in man following open heart surgery. *Circulation* 1977;56:737-745.
5. Wood KA, Eisenberg SJ, Kalman JM, Drew BJ, Saxon LA, Lee RJ, Lesh MD, Scheinman MM: Risk of thromboembolism in chronic atrial flutter. *Am J Cardiol* 1997;79:1043-1047.
6. Cauchemez B, Haissaguerre M, Fischer B, Thomas O, Clementy J, Coumel P: Electrophysiological effects of catheter ablation of inferior vena cava-tricuspid annulus isthmus in common atrial flutter. *Circulation* 1996;93:284-294.
7. Poty H, Saoudi N, Nair M, Anselme F, Letac B: Radiofrequency

- catheter ablation of atrial flutter: Further insights into the various types of isthmus block: Application to ablation during sinus rhythm. *Circulation* 1996;94:3204-3213.
8. Schwartzman D, Callans DJ, Gottlieb CD, Dillon SM, Movsowitz C, Marchlinski FE: Conduction block in the inferior vena caval-tricuspid valve isthmus: Association with outcome of radiofrequency ablation of type I atrial flutter. *J Am Coll Cardiol* 1996;28:1519-1531.

#### **IV. Ablation of VT**

Fellows should recognize the indications, patient selection, and risks and anticipated benefits of catheter ablation in VT associated with or without structural heart disease. It is reasonable to expect cure for the majority of patients with truly idiopathic VT, whereas catheter ablation usually is palliative in organic heart disease, especially in advanced ischemic heart disease.

##### **A. Idiopathic outflow tract VT<sup>1-3</sup>**

1. Sites
  - a. Right ventricular outflow tract
  - b. Left ventricular outflow tract
  - c. Anterobasal left ventricle
2. Mapping techniques
  - a. Activation sequence mapping; requires nonsustained or sustained VT
  - b. Pace mapping
  - c. Left ventricular outflow tract mapped via retrograde transaortic or transseptal approach

##### **B. Idiopathic left VT<sup>2,3</sup>**

1. Distinct ECG pattern of "right bundle, left axis" with site in an inferior/septal/apical area
2. Mechanism: Reentry incorporating portions of the His-Purkinje system
3. Principles of mapping and ablation
  - a. Activation mapping: Purkinje potential
  - b. Entrainment mapping
  - c. Pace mapping

##### **C. Bundle branch reentry<sup>4</sup>**

1. Generally occurs in patients with diffuse conduction system disease and nonischemic cardiomyopathies
2. Role of different maneuvers, comparison of HH and VV intervals

##### **D. Catheter ablation of postmyocardial infarction VT<sup>5-11</sup>**

1. Most appropriate as palliative therapy for frequent VT in patients with implantable defibrillators
2. Mechanism is reentry using pathways within and around large scars
3. Optimal approach is entrainment mapping during hemodynamically tolerated VT
4. Significance, sensitivity, and specificity of the following parameters:
  - a. Mid-diastolic potentials not dissociable from VT
  - b. Concealed entrainment
  - c. Postpacing intervals
  - d. Stimulus-QRS/local electrogram: QRS comparisons during entrainment and VT

#### **References**

1. Lerman BB, Stein K, Engelstein ED, Battleman DS, Lippman N, Bei D, Catanzaro D: Mechanism of repetitive monomorphic ventricular tachycardia. *Circulation* 1995;92:421-429.
2. Calkins H, Kalbfleisch SJ, El-Atassi R, Langberg JJ, Morady F: Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. *Am J Cardiol* 1993;71:827-833.
3. Coggins DL, Lee RJ, Sweeney J, Chein WW, Van Hare G, Epstein L, Gonzalez R, Griffin JC, Lesh MD, Scheinman MM: Radiofrequency catheter ablation as a cure for idiopathic ventricular tachycardia of both right and left ventricular origin. *J Am Coll Cardiol* 1994;23:1333-1341.
4. Cohen TJ, Chien WW, Lurie KG, Young C, Goldberg HR, Wang YS, Langberg JJ, Lesh MD, Lee MA, Griffin JC, Scheinman MM: Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: Results and long-term follow-up. *J Am Coll Cardiol* 1991;18:1767-1773.
5. Morady F, Harvey M, Kalbfleisch SJ, El-Atassi R, Calkins H, Langberg JJ: Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. *Circulation* 1993;87:363-372.
6. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Nattermann PD, Wiener I: Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. *Circulation* 1993;88(Pt 1):1647-1670.
7. Kim YH, Sosa-Suarez G, Trouton TG, O'Nunain SS, Osswald S, McGovern BA, Ruskin JN, Garan H: Treatment of ventricular tachycardia by transcatheter radiofrequency ablation in patients with ischemic heart disease. *Circulation* 1994;89:1094-1102.
8. Stevenson WG, Friedman PL, Sager PT, Saxon LA, Kocovic D, Harada T, Wiener I, Khan H: Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. *J Am Coll Cardiol* 1997;29:1180-1189.
9. Bogun F, Bahu M, Knight BP, Weiss R, Paladino W, Harvey M, Goyal R, Daoud E, Ching Man K, Strickberger SA, Morady F: Comparison of effective and ineffective target sites that demonstrate concealed entrainment in patients with coronary artery disease undergoing radiofrequency ablation of ventricular tachycardia. *Circulation* 1997;95:183-190.
10. Stevenson WG, Friedman PL, Kocovic D, Sager PT, Saxon LA, Pavri B: Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. *Circulation* 1998;98:308-314.
11. Soejima K, Suzuki M, Maisel WH, Brunckhorst CB, Delacretaz E, Blier L, Tung S, Khan H, Stevenson WG: Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: Short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. *Circulation* 2001;104:664-669.

#### **V. Pacemakers**

Knowledge of indications for temporary and permanent pacing and the technical ability to place both temporary and permanent pacemakers are critical elements of the training of a clinical electrophysiologist.<sup>1,2</sup>

- A. Temporary pacing
  1. Indications<sup>3</sup>
  2. Techniques
- B. Indications for permanent pacemaker implantation<sup>3</sup>
- C. Natural history of various bradyarrhythmias
- D. Evaluation techniques
- E. Effects of medications on sinus and AV node function
- F. Implantation (while minimal requirements of training program do not necessitate provision of implantation experience sufficient to perform pacemaker implantation, exposure adequate to assure a thorough understanding of concepts is critical)
  1. Anatomic considerations
    - a. Normal venous anatomy
    - b. Abnormal venous anatomy
      - i. Persistent left superior vena cava syndrome
      - ii. Subclavian occlusion
  2. Pocket location options
  3. Venous access techniques
  4. Cardiac sites for pacing
  5. Lead testing
  6. Pacing system analyzers
  7. Sensing evaluation

1. Lerman BB, Stein K, Engelstein ED, Battleman DS, Lippman N, Bei D, Catanzaro D: Mechanism of repetitive monomorphic ventricular tachycardia. *Circulation* 1995;92:421-429.
2. Calkins H, Kalbfleisch SJ, El-Atassi R, Langberg JJ, Morady F: Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. *Am J Cardiol* 1993;71:827-833.

- 8. Stimulation thresholds, including strength duration curves
- 9. Impedance measurements
- G. Follow-up
  - 1. Transtelephonic
  - 2. Clinic
  - 3. Troubleshooting
- H. Pacing system technology
  - 1. Leads (including electrodes, fixation, insulation, conductors, and connectors)
  - 2. Pulse generators (including batteries, circuitry, sensors, and function, including monitoring)
  - 3. Modes (including codes)
- I. Hemodynamics of pacing<sup>4</sup>
- J. Complications of pacing (including management)
- K. Lead extraction
  - 1. Indication
  - 2. Techniques
  - 3. Complications
- L. Device-device, device-drug, device-environmental interactions

## References

1. Ellenbogen KA, Kay GN, Wilkoff BL, eds: *Clinical Cardiac Pacing and Defibrillation*. Second Edition. WB Saunders, Philadelphia, PA, 2000.
2. Hayes DL, Lloyd MA, Friedman PA, eds. *Cardiac Pacing and Defibrillation: A Clinical Approach*. Futura Publishing Co., Armonk NY, 2000.
3. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1998;31:1175-1209.
4. Reynolds DW: Hemodynamics of cardiac pacing. In Ellenbogen KA, Wood MA, eds: *Cardiac Pacing*. Third Edition. Blackwell Scientific, Cambridge MA, 2000.

## VI. Implantable Cardioverter Defibrillators

A training program in clinical cardiac electrophysiology should include sufficient technical and clinical instruction in ICDs to allow the fellow to provide highly competent clinical assessment, patient selection, ICD implantation, and follow-up of patients with cardiac arrhythmias.

- A. Technologic and engineering principles<sup>1-4</sup>
  - 1. Leads and programmers as applied to the practice of cardiac electrophysiology
  - 2. Basic design and function of the ICD
  - 3. Defibrillation waveforms
  - 4. Lead systems
  - 5. Detection enhancements
  - 6. Diagnostic storage capabilities
- B. Indications and implantation guidelines for the ICD and appropriate integration of results of prospective trials into clinical decision-making<sup>5-9</sup>
- C. American College of Cardiology/American Heart Association (ACC/AHA), North American Society of Pacing and Electrophysiology (NASPE) guidelines for implantation of ICDs<sup>8</sup>
- D. Implantation techniques and testing of ICD system function at implantation<sup>1-4</sup>
- E. Indication and implantation of coronary sinus leads to enable biventricular pacing

- F. Drug-ICD and pacemaker-ICD interaction<sup>1-4</sup>
- G. Prevention of pacemaker-ICD interactions
- H. Complications<sup>1-4</sup>
  - I. Follow-up and troubleshooting<sup>1-4</sup>
  - J. Recommendations for driving for the ICD patient<sup>10</sup>
  - K. Cost-effectiveness of the ICD<sup>2,4</sup>
  - L. Quality of life and psychosocial impact of the ICD<sup>2,4</sup>

## References

1. Mower M, Schuer DB: Implantable defibrillators and its basic principles. In Podrid P, Kowey P, eds: *Cardiac Arrhythmias: Mechanisms, Diagnosis, and Management*. Williams & Wilkins, Baltimore, 1995, pp. 689-699.
2. Estes NAM, Manolis AS, Wang PJ: *Implantable Cardioverter Defibrillator: A Comprehensive Textbook*. Marcel Dekker, New York, 1994.
3. Singer I: *Implantable Cardioverter Defibrillator*. Futura Publishing Co., Armonk, NY, 1994.
4. Estes NAM: Implantable cardioverter defibrillator, electrophysiology self-assessment program II. American College of Cardiology, North American Society of Pacing and Electrophysiology. Book 8, 2000.
5. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC: A decade of clinical trial developments in post-myocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond. *J Cardiovasc Electrophysiol* 1998;9:864-891.
6. Cannom D, Marchlinski FE: Ventricular arrhythmias and sudden cardiac death, electrophysiology self-assessment program II. American College of Cardiology, North American Society of Pacing and Electrophysiology. Book 5, 2000.
7. Cannom DS, Prystowsky EN: Management of ventricular arrhythmias: Detection, drugs, and devices. *JAMA* 1999;28:171-179.
8. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1998;31:1175-1209.
9. Saksena S: Clinical investigations of antiarrhythmia devices: A statement for health care professionals from the North American Society of Pacing and Electrophysiology, the America College of Cardiology, and the Working Group on Arrhythmias and Cardiac Pacing of the European Society of Cardiology. *Circulation* 1995;91:2097-2109.
10. Epstein AE, Miles WM, Benditt DG, Camm AJ, Darline EJ, Friedman P, Garson A, Harvey JC, Kidwell GA, Klein GJ, Levine P, Marchlinski FE, Prystowsky E, Wilkoff B: Personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. *Circulation* 1996;64:1147-1166.

## Special Conditions

### I. Syncope

It is critical for the fellow to know that cardiac syncope carries a worse prognosis than other causes of syncope, and that syncope in the presence of cardiac disease may be a harbinger of impending sudden cardiac death.<sup>1-3</sup> Also important is the distinction between syncope occurring in individuals with and those without structural heart disease.

- A. Value of history, physical examination, and work-up for structural heart disease<sup>2,4</sup>
- B. Neurocardiogenic syncope
  - 1. Diagnosis<sup>5</sup>
  - 2. Sensitivity and specificity of tilt table test<sup>6</sup>
  - 3. Treatment<sup>7</sup>
    - a. Behavioral
    - b. Salt and fluids
    - c. Tilt training

- d. Pharmacologic
- e. Pacemaker
- C. Bradyarrhythmias
  - 1. Poor sensitivity of invasive electrophysiologic testing for diagnosis of bradycardias<sup>8,9</sup>
  - 2. Usefulness of implantable event monitors and long-term rhythm monitoring
- D. Tachyarrhythmias
  - 1. Sensitivity and specificity of invasive electrophysiologic testing in various types of structural heart disease<sup>8,10</sup>
    - a. Ischemic heart disease
    - b. Idiopathic dilated cardiomyopathy
    - c. Hypertrophic cardiomyopathy
    - d. Arrhythmogenic right ventricular dysplasia
    - e. No structural heart disease
- E. Indications for permanent pacemakers<sup>11</sup>
- F. Indications for ICDs<sup>11</sup>

## References

1. Kapoor WN: Evaluation and outcome of patients with syncope. Medicine 1990;69:160-175.
2. Linzer M, Yang EH, Estes NAM, Wang P, Vorperian VR, Kapoor WN: Diagnosing syncope; part 1: Value of history, physical examination, and electrocardiography. Ann Intern Med 1997;126:989-996.
3. Linzer M, Yang EH, Estes NAM, Wang P, Vorperian VR, Kapoor WN: Diagnosing syncope; part 2: Unexplained syncope. Ann Intern Med 1997;127:76-86.
4. Calkins H, Shyr Y, Frumin H, Schork A, Morady F: The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med 1995;98:365-373.
5. Grubb BP, Karas B: Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: An overview of classification, clinical evaluation, and management. PACE 1999;22:798-810.
6. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, Maloney JD, Raviele A, Ross B, Sutton R, Wolk MJ, Wood DL: ACC Expert Consensus Document: Tilt table testing for assessing syncope. J Am Coll Cardiol 1996;28:263-275.
7. Benditt DG, Fahy GJ, Lurie KG, Sakaguchi S, Fabian W, Sammiah N: Pharmacotherapy of neurally mediated syncope. Circulation 1999;100:1242-1248.
8. DiMarco JP: Value and limitations of electrophysiologic testing for syncope. Cardiol Clin 1997;15:219-232.
9. Krahn AD, Klein G, Yee R, Norris C: Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative noninvasive and invasive testing. Am J Cardiol 1998;82:117-119.
10. Zipes DP, DiMarco JP, Gillette PC, Jackman WM, Myerberg RJ, Rahimtoola SH: ACC/AHA task force report: Guidelines for clinical intracardiac electrophysiologic and catheter ablation procedures. J Am Coll Cardiol 1995;26:555-573.
11. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TBJ, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: Executive summary—A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation 1998;97:1175-1209.

## II. Sudden Cardiac Death

Electrophysiology fellows should be cognizant of the arrhythmic mechanisms that can cause sudden death; precipitants for arrhythmogenesis; evidence-based management of patients experiencing sudden death; role of pharmacologic and nonpharmacologic therapies; and principles of risk stratification and prophylactic approaches to patients who have not yet experienced sudden death.

- A. Definition and magnitude of the problem<sup>1,2</sup>
  1. Epidemiology
  2. Risk factors
- B. Arrhythmic mechanisms
  - 1. VT and ventricular fibrillation<sup>3</sup>
  - 2. Torsades de pointes<sup>4</sup>
  - 3. Genetic ion channel abnormalities
    - a. LQTS<sup>5</sup>
    - b. Brugada syndrome<sup>6</sup>
  - 4. Bradyarrhythmias (especially in patients with marked heart failure)<sup>7</sup>
- C. Precipitants<sup>1,2</sup>
  1. Myocardial ischemia
  2. Electrolyte abnormalities
  3. Autonomic nervous system abnormalities<sup>8</sup>
  4. Congestive heart failure
  5. Medications and role of proarrhythmia<sup>4,9</sup>
- D. Management
  1. ACLS guidelines<sup>10</sup>
  2. Evaluation and therapy of structural heart disease and ischemia, including echocardiography, exercise testing, cardiac catheterization, and indications for revascularization
  3. Role, sensitivity, and specificity of electrophysiologic testing to guide therapy
  4. Role of ICD therapy<sup>11</sup>
  5. Role of pharmacologic therapy
  6. Role of ablation and surgical therapies
  7. Role of ancillary therapies (e.g., beta-blockers, angiotensin-converting enzyme inhibitors, anti-ischemic therapies, etc.)
- E. Risk stratification
  1. Role, sensitivity, and specificity of programmed ventricular stimulation in patients with coronary artery disease, reduced left ventricular ejection fraction, and asymptomatic nonsustained VT<sup>12,13</sup>
  2. Role, sensitivity, and specificity of programmed ventricular stimulation in patients with nonischemic cardiomyopathy
  3. Role, sensitivity, and specificity of heart rate variability, signal-averaged ECG, T wave alternans, and QT dispersion to prognosticate risk in specific patient populations<sup>1</sup>
  4. Specific issues in athletes, including patient evaluation and limitation of activities<sup>14</sup>
  5. Specific considerations in patients with hypertrophic cardiomyopathies<sup>15</sup>
  6. Provocative maneuvers in patients with possible genetic ion channel abnormalities
- F. Completed clinical trials
  1. Antiarrhythmics Versus Implantable Defibrillators Trial (AVID)<sup>16</sup>
  2. Canadian Implantable Defibrillator Study (CIDS)<sup>17</sup>
  3. Cardiac Arrest Study Hamburg (CASH)
  4. Multicenter Automatic Defibrillator Implantation Trial (MADIT)<sup>13</sup>
  5. Multicenter Unsustained Tachycardia Trial (MUSTT)<sup>12</sup>
  6. Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)<sup>18</sup>
- G. Clinical trials in progress
  1. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

2. Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
3. Multicenter Automatic Defibrillator Implantation Trial (MADIT) II

## References

1. Zipes DP, Wellens HJ: Sudden cardiac death. *Circulation* 1998;98: 2334-2351.
2. Myerburg RJ, Interian AJ, Mitrani RM, Kessler KM, Castellanos A: Frequency of sudden cardiac death and profiles of risk. *Am J Cardiol* 1997;80:10F-19F.
3. Jalife J: Ventricular fibrillation: Mechanisms of initiation and maintenance. *Annu Rev Physiol* 2000;62:25-50.
4. Roden DM: Mechanisms and management of proarrhythmia. *Am J Cardiol* 1998;82:49I-57I.
5. Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM: Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II. *Circulation* 1999;99:518-528.
6. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR: The Brugada syndrome: Clinical, electrophysiologic and genetic aspects. *J Am Coll Cardiol* 1999;33:5-15.
7. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J: Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. *Circulation* 1989;80:1675-1680.
8. Leor J, Poole WK, Kloner RA: Sudden cardiac death triggered by an earthquake. *N Engl J Med* 1996;334:413-419.
9. CAST Investigators: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. *N Engl J Med* 1989;321:406-412.
10. International guidelines 2000 for CPR and ECC: A consensus on science. *Circulation* 2000;102(Suppl):8.
11. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TBJ, Freedman RA, Hlatky MA, Naccarelli GV, Saksena S, Schlant RC, Silka MJ: ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: Executive summary—A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). *Circulation* 1998;97:1175-1209.
12. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999;341:1882-1890.
13. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;335:1933-1940.
14. Maron BJ: Heart disease and other causes of sudden death in young athletes. *Curr Probl Cardiol* 1998;23:477-529.
15. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Borhani G, Estes NA, Spirito P: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:365-373.
16. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. *N Engl J Med* 1997;337:1576-1583.
17. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B: Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000;101: 1297-1302.
18. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. *N Engl J Med* 1995;333:77-82.

## Appendix

### Author Affiliations

*Mark S. Link, M.D.*, New England Medical Center, Boston, MA; *Charles Antzelevitch, Ph.D.*, Masonic Medical Research Laboratory, Utica, NY; *Albert L. Waldo, M.D.*, University Hospitals of Cleveland Cardiology, Cleveland, OH; *Augustus O. Grant, M.D.*, Duke University Medical Center, Durham, NC; *John P. DiMarco, M.D.*, University of Virginia School of Medicine, Charlottesville, VA; *Mark E. Josephson, M.D.*, Beth Israel Deaconess Medical Center, Boston, MA; *Francis E. Marchlinski, M.D.*, University of Pennsylvania, Philadelphia, PA; *Hasan Garan, M.D.*, Columbia-Presbyterian Medical Center, New York, NY; *Philip T. Sager, M.D.*, Schering-Plough Research Institute, Kenilworth, NJ; *Dwight W. Reynolds, M.D.*, University of Oklahoma Health Sciences Center, Oklahoma City, OK; *Pablo Denes, M.D.*, Northwestern Memorial Hospital Cardiology, Chicago, IL; *Melvin M. Scheinman, M.D.*, University of California, San Francisco, San Francisco, CA; *N.A. Mark Estes III, M.D.*, New England Medical Center, Boston, MA.